Improving Ventilatory Capacity in Those With Chronic High Level SCI

NCT ID: NCT05041322

Last Updated: 2025-09-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 13 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-11-29
• Study Completion Date: 2024-11-01

Brief Summary

The purpose of this study is to find out if taking the drug Buspar will increase breathing capacity in individuals with spinal cord injuries.

Detailed Description

Chemoreceptive regulatory feedback is crucial for precise ventilatory control, especially during exercise. However, individuals with high-level SCI have a reduced chemoreceptive drive to breathe. Studies have shown lesser increases in minute ventilation and mouth pressure during hypercapnia in those with tetraplegia. Peripheral factors rather than central factors appear to cause the reduction of the ventilatory response to hypercapnia. This reduced ventilatory drive may have functional impact on exercise ventilation in patients with high level SCI and enhancing ventilatory drive may improve exercise ventilation in high-level SCI.

Currently, there are no treatments to overcome these functional deficits that affect daily activity and exercise-based rehabilitation recovery. However, previous work in an animal model of SCI has found that that a serotonin agonist markedly increases respiratory responses to carbon dioxide. Treatment with a serotonin 5HT1A agonist effectively improved the ventilatory drive after both acute and chronic spinal cord injuries in rats. One potential mechanism is increased excitability of the ventral motoneurons that have survived the spinal cord injury. 5-HT1A receptors do exist on these neurons, and when activated, amplify the excitatory output. Another mechanism resides at the intercostal and abdominal muscle afferents which influence supraspinal respiratory group neurons in the brainstem and motor output to the muscles of breathing. Hence, serotonin agonists may act on neural pathways in the spinal cord responsible for transferring afferent information from intercostal muscles to supraspinal centers. Lastly, 5-HT1A receptors may also be involved in functional plasticity of neural respiratory pathways, in particular ipsilateral phrenic nerve activity. Up regulation of 5-HT1A receptors due to denervation supersensitivity could result in postsynaptic hyperresponsivity due to loss of descending input.

BuSpar/Buspirone is a serotonin 5HT1A agonist and used as an anxiolytic in humans. It does not cause sedation, has minimal effects on psychomotor performance or cognition, and has low threshold for abuse potential or dependence liability. Prior studies have found Buspirone to be well tolerated. It has been used safely in spinal cord injury, but not for respiratory purposes. (Though there is one clinical trial in process: Role of Enhancing Serotonin Receptors Activity for Sleep Apnea Treatment in Patients with SCI.) However, Buspirone up to 60 mg daily has been used to treat disturbed respiratory rhythms in multiple sclerosis, brain cancer, and brainstem infarction. Interestingly, in patients with COPD, a 14-day oral administration of buspirone (20 mg) found improved anxiety and depression as well as increased exercise tolerance with lesser sensations of dyspnea. Hence, buspirone may offer a treatment to improve hypercapnic ventilatory drive. Given that oral administration of 30 mg results in peak plasma levels at one hour and that the average elimination half life is about 2 to 3 hours, buspirone is an attractive and safe approach to exploring the ability to improve respiratory responses to exercise and/or hypercapnia exposure in those with high level spinal cord injury that limits breathing capacity.

Conditions

Spinal Cord Injuries

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Study Groups

Placebo

Subjects take placebo pills (twice a day) for 14 Days.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Subjects take placebo pills (twice a day) for 14 Days.

Buspirone

Subjects take 30 mg buspirone HCl (15 mg twice a day) for 14 Days.

Other Names:

Buspar

Group Type: ACTIVE_COMPARATOR

Buspirone

Intervention Type: DRUG

Subjects take 30 mg buspirone HCl (15 mg twice a day) for 14 Days.

Interventions

Buspirone

Subjects take 30 mg buspirone HCl (15 mg twice a day) for 14 Days.

Intervention Type: DRUG

Placebo

Subjects take placebo pills (twice a day) for 14 Days.

Intervention Type: DRUG

Other Intervention Names

BuSpar, Buspirone Hydrochloride; Control

Eligibility Criteria

Inclusion Criteria

• Chronic high-level SCI (at least 24-months post injury)
• Age 18 to 50 years.
• Medically stable
• Spinal Cord Injury ≥T3
• American Spinal Injury Association grade A or B or C.
• Able to perform arm crank exercise.

Exclusion Criteria

• Cardiomyopathy
• High blood pressure( >140/90 mmHg or you are taking high blood pressure medication)
• Significant irregular heartbeat
• Heart disease
• Chronic lung disease (COPD, bronchitis)
• Current use of cardioactive or antidepressant drugs
• Family history of significant irregular heart beat or sudden cardiac death
• Orthostatic hypotension (symptomatic fall in blood pressure >30 mmHg when upright)
• Current grade 2 or greater pressure ulcers at relevant contact site
• Neurological disease (stroke, peripheral neuropathy, myopathy)
• Arm or shoulder conditions that limit ability to perform arm crank exercise
• History of bleeding disorder, diabetes, kidney disease, cancer, other neurological disease
• Recent weigh change (greater than 10 pounds)
• Regular use of tobacco
• Intrathecal baclofen pump,
• Current use of cardioactive, antidepressant, other sedating agents
• Suicidal ideation
• Pregnant and/or breastfeeding women.

In addition, subjects must have no known hypersensitivity to Buspar and must not be taking a monoamine oxidase inhibitor.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Spaulding Rehabilitation Hospital

OTHER

Sponsor Role: lead

Responsible Party

J. Andrew Taylor

Ph.D., Director, Cardiovascular Research Laboratory

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Spaulding Hospital Cambridge

Cambridge, Massachusetts, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

2016P002409

Identifier Type: -

Identifier Source: org_study_id